Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,073
  • Shares Outstanding, K 11,434
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,420 K
  • 60-Month Beta 1.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56
Trade TARA with:

Options Overview Details

View History
  • Implied Volatility 96.62% ( +8.54%)
  • Historical Volatility 74.44%
  • IV Percentile 32%
  • IV Rank 17.94%
  • IV High 473.68% on 11/30/23
  • IV Low 14.20% on 08/09/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 155
  • Volume Avg (30-Day) 109
  • Put/Call OI Ratio 1.34
  • Today's Open Interest 3,583
  • Open Int (30-Day) 3,580

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.82
  • Number of Estimates 2
  • High Estimate -0.55
  • Low Estimate -1.09
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +18.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +14.94%
on 04/19/24
3.35 -10.45%
on 04/22/24
-0.19 (-5.96%)
since 04/10/24
3-Month
2.61 +14.94%
on 04/19/24
5.24 -42.75%
on 04/05/24
-0.05 (-1.64%)
since 02/09/24
52-Week
1.04 +188.46%
on 11/22/23
5.24 -42.75%
on 04/05/24
-0.26 (-7.98%)
since 05/10/23

Most Recent Stories

More News
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents...

TARA : 3.00 (+0.67%)
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 3.00 (+0.67%)
Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash...

TARA : 3.00 (+0.67%)
Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable,...

TARA : 3.00 (+0.67%)
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 3.00 (+0.67%)
Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 687.9% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable,...

TARA : 3.00 (+0.67%)
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021...

TARA : 3.00 (+0.67%)
Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 3.00 (+0.67%)
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 3.00 (+0.67%)
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...

TARA : 3.00 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 3.74
2nd Resistance Point 3.54
1st Resistance Point 3.27
Last Price 3.00
1st Support Level 2.80
2nd Support Level 2.60
3rd Support Level 2.33

See More

52-Week High 5.24
Fibonacci 61.8% 3.64
Fibonacci 50% 3.14
Last Price 3.00
Fibonacci 38.2% 2.64
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar